A national survey examining obstetrician perspectives on use of 17-alpha hydroxyprogesterone caproate post-US FDA approval

Clinical Drug Investigation

Volumn 33, Issue 8, 2013, Pages 571-577

  Rebarber, Andrei ^a,b,c,d   Fox, Nathan ^a,b,c   Klauser, Chad K ^a,b,c   Saltzman, Daniel ^a,b,c   Roman, Ashley S ^a,b,c  

^a PLLC   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYPROGESTERONE CAPROATE;

ARTICLE; AWARENESS; BODY WEIGHT; CERTIFICATION; FEMALE; FOOD AND DRUG ADMINISTRATION; HEALTH SURVEY; HUMAN; LEGAL LIABILITY; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; PERCEPTION; PHYSICIAN ATTITUDE; PREGNANCY; PREMATURE LABOR; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE;

17-ALPHA-HYDROXYPROGESTERONE; ATTITUDE OF HEALTH PERSONNEL; DATA COLLECTION; DRUG APPROVAL; FEMALE; HUMANS; MALE; OBSTETRICS; PHYSICIAN'S PRACTICE PATTERNS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84880873764     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-013-0099-4     Document Type: Article

References (14)

1. Meis PJ, Klebanoff M, Thom E, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med. 2003;348(24):2379-85.
2. Martin JA, Hamilton BE, Sutton PD, et al. Births: final data for 2008. Natl Vital Stat Syst. 2010;59(1):1, 3-71.
3. Goldstein P, Berrier J, Rosen S, et al. A meta-analysis of randomized control trials of progestational agents in pregnancy. Br J Obstet Gynaecol. 1989;96(3):265-74.
4. Sanchez-Ramos L, Kaunitz AM, Delke I. Progestational agents to prevent preterm birth: a meta-analysis of randomized controlled trials. Obstet Gynecol. 2005;105(2):273-9.
5. U.S Department of Health and Human Services. FDA statement on Makena; 2011. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2011/ucm249025. htm. Accessed 18 June 2013.
6. Ness A, Dias T, Damus K, et al. Impact of the recent randomized trials on the use of progesterone to prevent preterm birth: a 2005 follow-up survey. Am J Obstet Gynecol. 2006;195(4):1174-9.
7. Henderson ZT, Power ML, Berghella V, et al. Attitudes and practices regarding use of progesterone to prevent preterm births. Am J Perinatol. 2009;26(7):529-36.
8. ACOG Committee Opinion. Use of progesterone to reduce preterm birth. Obstet Gynecol. 2003;102(5 Pt 1):1115-6.
9. ACOG Committee Opinion number 419 October 2008 (replaces no. 291, November 2003). Use of progesterone to reduce preterm birth. Obstet Gynecol. 2008;112(4):963-5.
10. O'Brien JM, Adair CD, Lewis DF, et al. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol. 2007;30(5):687-96.
11. da Fonseca EB, Bittar RE, Carvalho MH, et al. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol. 2003;188(2):419-24.
12. Mahaguna V, McDermott JM, Zhang F, et al. Investigation of product quality between extemporaneously compounded progesterone vaginal suppositories and an approved progesterone vaginal gel. Drug Dev Ind Pharm. 2004;30(10):1069-78.
13. Johnson JW, Austin KL, Jones GS, et al. Efficacy of 17alpha- hydroxyprogesterone caproate in the prevention of premature labor. N Engl J Med. 1975;293(14):675-80.
14. Rebarber A, Fox NS, Klauser CK, et al. Using 17 alpha-hydroxyprogesterone caproate to impact rates of recurrent preterm delivery in clinical practice. J Matern Fetal Neonatal Med. 2010;23(10):1139-42.